Abstract
Rheumatoid arthritis (RA) is a chronic inflammatory disease that involves synovial tissue and leads to joint destruction. There are currently 5 tumor necrosis factor (TNF) antagonists licensed for the treatment of RA. This review summarizes the predictors of response to TNF antagonists in RA. Demographic variables were found to predict response, although not consistently. The variables associated with poor clinical response were presence of radiographic joint erosions at baseline, poor functional capacity at baseline, presence of human antibodies against TNF chimeric antibodies, and increase in anti-DNA and antinuclear antibodies. In selected populations, polymorphisms of TNF, TNF receptor, and Fc γ receptor were related to clinical response. Expression of TNF and other inflammatory cytokines in synovial tissue was explored. The heterogeneity of study populations limits the generalizability of the results in most studies.
Keywords: Rheumatoid arthritis, response, biomarkers, TNF antagonists.
Current Pharmaceutical Design
Title:Predictors of Response to TNF Antagonists
Volume: 21 Issue: 2
Author(s): Eva Salgado, Jose Ramon Maneiro and Juan J. Gomez-Reino
Affiliation:
Keywords: Rheumatoid arthritis, response, biomarkers, TNF antagonists.
Abstract: Rheumatoid arthritis (RA) is a chronic inflammatory disease that involves synovial tissue and leads to joint destruction. There are currently 5 tumor necrosis factor (TNF) antagonists licensed for the treatment of RA. This review summarizes the predictors of response to TNF antagonists in RA. Demographic variables were found to predict response, although not consistently. The variables associated with poor clinical response were presence of radiographic joint erosions at baseline, poor functional capacity at baseline, presence of human antibodies against TNF chimeric antibodies, and increase in anti-DNA and antinuclear antibodies. In selected populations, polymorphisms of TNF, TNF receptor, and Fc γ receptor were related to clinical response. Expression of TNF and other inflammatory cytokines in synovial tissue was explored. The heterogeneity of study populations limits the generalizability of the results in most studies.
Export Options
About this article
Cite this article as:
Salgado Eva, Ramon Maneiro Jose and Gomez-Reino Juan J., Predictors of Response to TNF Antagonists, Current Pharmaceutical Design 2015; 21 (2) . https://dx.doi.org/10.2174/1381612820666140825124152
DOI https://dx.doi.org/10.2174/1381612820666140825124152 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Palmitoylethanolamide in Homeostatic and Traumatic Central Nervous System Injuries
CNS & Neurological Disorders - Drug Targets Plasticity in Uterine Innervation: State of the Art
Current Protein & Peptide Science HIV: A Raft-Targeting Approach for Prevention and Therapy Using Plant-Derived Compounds (Review)
Current Drug Targets New Molecular Targets of Anticancer Therapy – Current Status and Perspectives
Current Medicinal Chemistry Selective VEGFR Inhibitors for Anticancer Therapeutics in Clinical Use and Clinical Trials
Current Pharmaceutical Design Oxidative Stress in the Early Stage of Psychosis
Current Topics in Medicinal Chemistry Recent Advances in Half-life Extension Strategies for Therapeutic Peptides and Proteins
Current Pharmaceutical Design Disease Modifying Drugs in Multiple Sclerosis: Mechanisms of Action and New Drugs in the Horizon
CNS & Neurological Disorders - Drug Targets Ganoderma lucidum: A Potential for Biotechnological Production of Anti-Cancer and Immunomodulatory Drugs
Recent Patents on Anti-Cancer Drug Discovery It is All About Proteases: From Drug Delivery to In Vivo Imaging and Photomedicine
Current Medicinal Chemistry Possible Mechanisms of Lymphoma Development in Sjogren’s Syndrome
Current Immunology Reviews (Discontinued) Computer Aided Discovery of Potential Anti-inflammatory (S)-naproxen Analogs as COX-2 Inhibitors
Medicinal Chemistry Dihidro-β-Agarofuran Sesquiterpenes: A New Class of Reversal Agents of the Multidrug Resistance Phenotype Mediated by P-Glycoprotein in the Protozoan Parasite Leishmania
Current Pharmaceutical Design Structure-Activity Relationship Studies on ADAM Protein-Integrin Interactions
Cardiovascular & Hematological Agents in Medicinal Chemistry MICA Gene and Relevance to Immune Responses in Organ Transplants and Inflammatory, Tumoral and Autoimmune Diseases
Current Immunology Reviews (Discontinued) Herbal Nano Formulations: Patent and Regulatory Overview
Applied Clinical Research, Clinical Trials and Regulatory Affairs Genetic Variations in Telomere Maintenance, with Implications on Tissue Renewal Capacity and Chronic Disease Pathologies
Current Pharmacogenomics and Personalized Medicine Synthesis of Celecoxib and Structural Analogs- A Review
Current Organic Chemistry Modulation of Inflammatory Response to Implanted Biomaterials Using Natural Compounds
Current Pharmaceutical Design The Metabolic Rationale for a Lack of Cross-reactivity Between Sulfonamide Antimicrobials and Other Sulfonamide-containing Drugs
Drug Metabolism Letters